Vijay Shreedhar Net Worth

The estimated Net Worth of Vijay Shreedhar is at least $2.66 Million dollars as of 21 June 2021. Mr. Shreedhar owns over 6,200 units of Adamas Pharmaceuticals Inc stock worth over $1,362,342 and over the last 5 years he sold ADMS stock worth over $66,617. In addition, he makes $1,230,090 as Chief Commercial Officer at Adamas Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Shreedhar ADMS stock SEC Form 4 insiders trading

Vijay has made over 3 trades of the Adamas Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 6,200 units of ADMS stock worth $31,992 on 21 June 2021.

The largest trade he's ever made was selling 6,200 units of Adamas Pharmaceuticals Inc stock on 21 June 2021 worth over $31,992. On average, Vijay trades about 1,681 units every 20 days since 2019. As of 21 June 2021 he still owns at least 165,735 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Mr. Shreedhar stock trades at the bottom of the page.

Vijay Shreedhar biography

Vijay Shreedhar serves as Chief Commercial Officer of the Company. Prior to joining Adamas, Dr. Shreedhar served in a variety of sales and marketing roles of increasing responsibility in multiple therapeutic areas at Amgen, a biotechnology company, from August 2005 to May 2019. Most recently, he was Executive Director and Integrated Commercial Lead for the Multiple Myeloma franchise with responsibility for national sales, brand marketing and regional marketing teams. Dr. Shreedhar holds a Ph.D. in Oncology and Immunology from the University of Texas, M.D. Anderson Cancer Center and an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania

What is the salary of Vijay Shreedhar?

As the Chief Commercial Officer of Adamas Pharmaceuticals Inc, the total compensation of Vijay Shreedhar at Adamas Pharmaceuticals Inc is $1,230,090. There are 1 executives at Adamas Pharmaceuticals Inc getting paid more, with Neil McFarlane having the highest compensation of $2,080,640.

How old is Vijay Shreedhar?

Vijay Shreedhar is 49, he's been the Chief Commercial Officer of Adamas Pharmaceuticals Inc since 2019. There are 8 older and 4 younger executives at Adamas Pharmaceuticals Inc. The oldest executive at Adamas Pharmaceuticals Inc is Ivan Lieberburg, 70, who is the Independent Director.

What's Vijay Shreedhar's mailing address?

Vijay's mailing address filed with the SEC is C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE, CA, 94608.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney, and William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Mr. Shreedhar stock trades at Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director